Form 4: Director Julia Haller Acquires Deferred Share Units in Bristol-Myers Squibb

Julia Haller, a director of Bristol-Myers Squibb, acquired 3,562.341 deferred share units on February 1, 2025, at a price of $58.95 per unit.

Summary

• On February 1, 2025, Julia Haller, a director at Bristol-Myers Squibb, acquired 3,562.341 deferred share units.
• The price per deferred share unit was $58.95.
• These units will convert into shares of common stock upon settlement, which occurs when Haller ceases to be a director or at a previously specified future date.
• Following the transaction, Haller beneficially owns 32,223.091 deferred share units, which includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of a director's compensation in the form of deferred share units.

Future Outlook

The deferred share units will be converted into common stock upon settlement when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors, offering insights into their confidence in the company's future performance.

Stakeholder Impact

• The acquisition of deferred share units by a director may signal confidence in the company's future performance to shareholders.

Key Dates

Keywords

Deferred Share Units, Director, Beneficial Ownership, Bristol-Myers Squibb, BMY, Julia Haller, Form 4, SEC Filing